新修订《药品管理法实施条例》发布利好加持，今日（1月28日），港股通创新药板块止跌回暖，龙头 股集体起立，石药集团大涨6.14%，百济神州涨4.06%，信达生物涨3.3%。 港股通创新药ETF（520880）重仓创新药龙头，盘中一度涨超1.5%，收涨1.33%收复5日线，放量成交 3.44亿元。 政策继续加码或为创新药行情导火索。1月27日，新修订《药品管理法实施条例》发布，这是条例实施 二十多年来首次全面修订。 据国家药监局相关人士介绍，此次条例修订旨在激励医药创新，明确支持以临床价值为导向，研究和创 制新药，并首次引入了儿童用药品、罕见病药品市场独占期制度，推动药物研发，更好地服务患者临床 用药需求。在制度设计方面，条例明确规定了药品上市的快速审评通道，加快新药好药上市。 业内人士指出，新条例有望显著提升相关领域研发热情，利好创新药企长期发展。设立药品试验数据保 护制度和市场独占期制度，有助于推动中国医药产业从"仿制为主"向"创新驱动"战略转型。 就港股创新药二级市场走势，西部证券认为，2026年，港股创新药或将延续结构性行情。从投资逻辑来 看，BD出海加速，中美创新药价差收敛、创新药企业市值差距收窄，将 ...

Group 1 - The core viewpoint of the article is that the Ministry of Commerce and nine other departments have jointly issued opinions to promote the high-quality development of the pharmaceutical retail industry, transitioning from a "single drug sales" model to a "health service" model [1] - The policy encourages mergers, acquisitions, and horizontal consolidation, which is expected to accelerate the clearance of individual pharmacies and enhance industry concentration [1] - The optimization of external prescription reviews and the establishment of pharmacy service platforms are aimed at facilitating prescription outflow and market expansion [1] Group 2 - Retail pharmacies are encouraged to expand their business scope to include health consultations, traditional Chinese medicine culture, elderly care, and convenient retail services, thereby creating a comprehensive health service entity [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which includes listed companies engaged in innovative drug research and development, covering areas such as biological products, chemical drugs, and traditional Chinese medicine [1]

Group 1 - The core viewpoint of the articles highlights the Chinese government's initiatives to promote high-quality development in the pharmaceutical retail industry, including encouraging participation in centralized procurement and supporting mergers and acquisitions among retail pharmacies [1] - The Chinese pharmaceutical export value reached $100.895 billion in the first 11 months of 2025, indicating a continuous optimization of product structure [1] - Traditional products such as traditional Chinese medicine and chemical active pharmaceutical ingredients maintain a strong global market share, with export scales continuing to grow [4] Group 2 - Chinese pharmaceutical companies set a record of $135.7 billion through multinational licensing agreements in 2025, showing significant year-on-year growth and increasing global recognition of Chinese pharmaceutical innovation [4] - Strengthened cooperation between China and ASEAN has led to the establishment of a pharmaceutical trade regional platform, with transaction volumes exceeding 10 million RMB and attracting 224 companies, thereby promoting regional trade [4] - The platform is built on transparency, regulatory credibility, and public health commitments, serving as a valuable bridge of trust between ASEAN countries and China [4]

Core Insights - The article highlights the growing trend of Chinese pharmaceutical and medical device exports, emphasizing the importance of innovation and international collaboration in this sector [1][2][3][4] Group 1: Export Growth and Market Opportunities - China's pharmaceutical exports reached $100.895 billion in the first 11 months of 2025, with a focus on optimizing product structure and increasing the share of innovative drugs and high-performance medical devices [1] - Exports to the Belt and Road Initiative (BRI) markets amounted to $34.43 billion, indicating significant market potential in these regions [2] - The establishment of cross-border procurement platforms, such as the China-ASEAN procurement platform, has facilitated over $10 million in transactions, attracting 224 domestic pharmaceutical companies [2] Group 2: Policy Support and Infrastructure Development - Multiple government departments are collaborating to create a comprehensive service platform for companies looking to expand internationally, including investment guides and risk assessment reports for over 170 countries [1] - The National Medical Products Administration has approved 76 innovative drugs and 76 innovative medical devices in 2025, leading the world in approvals [3] - The establishment of specialized platforms for regions like Central Asia and Eastern Europe is underway, with significant export sales already achieved [2] Group 3: Strategic Approaches and Investment - Companies are encouraged to develop experienced professional teams and tailored strategies for international expansion, leveraging foreign aid projects to provide comprehensive health solutions [3] - Investment in core technology research and development is critical, as exemplified by Heng Rui Medicine's cumulative R&D investment exceeding $50 billion, with over $20 billion in the last three years alone [3] - The total value of overseas licensing agreements for Chinese pharmaceuticals surpassed $130 billion in 2025, reflecting a strong focus on meeting real health needs and aligning with international standards [4]

Core Viewpoint - The Shandong provincial government has issued an implementation opinion aimed at deepening the reform of drug and medical device regulation, promoting high-quality development in the pharmaceutical industry through 29 specific measures across six key areas [2]. Group 1: Strengthening Innovation - The implementation opinion emphasizes the importance of medical innovation, focusing on cutting-edge areas such as gene therapy, cell therapy, synthetic biology, AI-assisted drug design, new vaccines, radioactive drugs, high-end medical devices, and modernization of traditional Chinese medicine [2]. - Shandong will support projects with significant original innovations and breakthroughs through provincial science and technology programs, enhancing the innovation platform system and encouraging enterprise-led innovation [2]. Group 2: Regulatory Efficiency - The reform aims to enhance efficiency by streamlining the review and approval process, integrating with the Beijing-Tianjin-Hebei review center to access more resources for drug and medical device evaluations [4]. - A scientific tiered review mechanism will be established, providing dedicated support for key innovative products while optimizing standardized review processes for routine projects to improve efficiency [4]. - The reform represents a systematic restructuring and digital transformation of the review and approval system, promoting full online processing of drug and medical device registrations and licenses, allowing for a more efficient workflow [4].

Core Viewpoint - Liaoning Province is actively engaging with a delegation of renowned pharmaceutical companies to enhance cooperation and investment in the region's pharmaceutical industry, aiming to establish itself as a key hub for pharmaceutical innovation by 2030 [1] Group 1: Investment and Cooperation - The investment delegation consists of representatives from 12 Fortune 500 pharmaceutical companies and 6 well-known domestic and international pharmaceutical enterprises [1] - The delegation aims to leverage this visit to foster communication and collaboration, seeking to identify synergies and promote high-quality projects and innovative products in Liaoning [1] Group 2: Industry Development - Liaoning is a major production area for traditional Chinese medicine, particularly "Northern Medicine," with several categories ranking first in national output [1] - The province has a comprehensive pharmaceutical industry structure, including research, manufacturing, distribution, and services, supported by numerous research institutions and innovation platforms [1] - The provincial government is prioritizing biomedicine and advanced medical equipment as key emerging industries, with plans to establish a full-chain support mechanism for pharmaceutical innovation [1] Group 3: Future Goals - By 2030, Liaoning aims to become a leading center for pharmaceutical innovation in Northeast China and a production base for critical pharmaceutical raw materials and high-end medical devices [1]

Group 1 - The core viewpoint of the article highlights that the company, 泰恩康 (301263), is accelerating the clinical development of CKBA in response to national policies supporting pharmaceutical innovation [1] Group 2 - For the adult vitiligo indication, the company is steadily advancing the application process for the Phase III clinical trial [1] - The application for the Phase II clinical trial for the 2-12 years old children's vitiligo indication has been accepted by the drug regulatory authority, and the company will disclose updates if approved [1] - CKBA has obtained the seamless adaptive clinical trial approval for the Phase II/III indication of rosacea, and the company is actively preparing for ethical review and subject enrollment [1]

Group 1 - The core viewpoint is that the Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the ETF (520880) showing a 2% increase and breaking above the 60-day moving average, indicating a potential reversal trend as of January 8 [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has undergone a significant adjustment, with a decline of over 24% since early September 2025, suggesting that the current period may be an optimal time for medium to long-term investment in core innovative drug assets [1] - The long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance signaling good opportunities for innovative drugs and medical devices in 2026 [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF (520880) and its associated off-market fund (025221) present a low-entry window, characterized by three unique advantages: purity and comprehensiveness, significant representation of leading companies, and better risk control through forced de-weighting of less liquid stocks [2] - The top ten innovative drug leaders account for over 73% of the index, highlighting the strength of the innovative drug sector [2] - The focus for 2026 will likely remain on "innovation + internationalization," with an emphasis on innovative drugs that show positive industry trends and increasing global competitiveness [1][2]

Core Insights - China is enhancing support for innovative drugs with new mechanisms and targets across the entire chain of communication, clinical trials, registration, and review processes to facilitate "China's first launch" of innovative drugs [1][2] - By 2025, there is an expectation for a significant increase in the market launch of urgently needed clinical products in the pharmaceutical and medical device sectors [1] Group 1: Pharmaceutical Sector - In 2022, the National Medical Products Administration (NMPA) approved a total of 4,087 drug registration applications, including 76 innovative drugs, marking a historical high [1] - The time gap for domestic and international drug listings has been reduced, with 59 foreign new drugs receiving temporary import approval [1] - A total of 138 children's drugs were approved, and 48 rare disease drugs were granted temporary import approval, addressing medication gaps for special populations [1] Group 2: Medical Device Sector - The NMPA approved 3,402 medical device products in 2022, including 76 innovative medical devices, achieving a new record [1] - The medical device innovation ecosystem is continuously improving, supporting industry upgrades [1][2] - In 2026, the NMPA plans to expedite the market launch of high-end medical devices and allocate more review resources to urgently needed innovative devices and those for rare disease prevention [2] Group 3: Future Initiatives - The NMPA will implement a drug trial data protection system and establish market exclusivity for children's and rare disease medications [2] - There will be a focus on optimizing the review and approval measures for cell and gene therapy drugs [2] - The establishment of a national standardized technical working group for intelligent frontier medical devices is planned to advance standard formulation in key areas such as brain-machine interfaces [2]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is showing strong performance, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing a significant increase of 5.22% and a trading volume surge of nearly 200% compared to the previous trading day [1][7]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) covers 37 innovative drug research companies, with 36 stocks showing gains, including a rise of over 11% for InnoCare Pharma-B and over 8% for Kelun-B [1][7]. - Major weighted stocks such as Innovent Biologics, Rongchang Biopharmaceuticals, and BeiGene all increased by over 6% [1][7]. Group 2: Regulatory and Market Trends - According to the National Medical Products Administration, 76 innovative drugs are expected to be approved for market in China by 2025, a significant increase from 48 in 2024, marking a historical high [9][10]. - The domestic innovative drugs are particularly notable, accounting for 80.85% in chemical drugs and 91.30% in biological products [9][10]. Group 3: Market Opportunities - The total value of innovative drug licensing transactions in China is projected to exceed $130 billion in 2025, with over 150 transactions, both figures representing historical records and significant increases from 2024 [10]. - China's pipeline of new drugs currently holds a 30% share of the global total, ranking second worldwide [10]. Group 4: Investment Insights - Huafu Securities emphasizes that the long-term logic of pharmaceutical innovation remains unchanged, suggesting a positive outlook for innovative drugs in 2026 following a market adjustment in the second half of 2025 [10]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has unique advantages in asset allocation [10].